A study of a new aortic valve replacement for a specific type of heart valve problem
Part of Heart & circulation clinical trials.
This study looks at how safe and effective the SAPIEN 3 valve is for patients in China who have a specific type of bicuspid aortic valve (Type-0) that is severely narrowed. If you have severe aortic stenosis and meet the criteria, this treatment might be an option for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 50 years or older.
- You have severe aortic stenosis, meaning your heart valve is very narrow and doesn't open well (confirmed by tests like echocardiogram).
- You have been diagnosed with Type-0 bicuspid aortic valve (a specific two-leaflet valve structure) by a special CT scan.
- You are willing to have the valve replacement procedure and come back for all follow-up visits.
- You have adequate blood vessels in your leg to allow the valve to be inserted through a catheter.
- You do not have major medical issues that would make the procedure unsafe, such as severe artery disease, need for open heart surgery, or a very weak heart pump.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a newer artificial heart valve (Sapien 3) placed through a small tube in the leg, for younger people (50–70) with severe aortic stenosis. It aims to see if this less invasive option works well in this age group.
This study is testing a new heart valve called the SAPIEN 3 Ultra RESILIA valve for people with severe aortic stenosis. Researchers want to see how well it works and how safe it is over 10 years after a minimally invasive valve replacement procedure called TAVI.
This trial studies a new “valve-in-valve” procedure to treat a failing aortic bioprosthetic valve. It may help people improve blood flow through the heart valve and reduce valve-related problems.
This trial studies whether a new through-the-blood-vessel heart valve (TAVR) is safe and works well for people with severe aortic stenosis who are too risky for traditional surgery. If you qualify, you would be closely followed to check your symptoms and valve function over time.
This study follows patients with severe aortic stenosis who get a new heart valve (the SAPIEN 3 Ultra RESILIA) through a less invasive procedure (TAVR). Researchers want to see how well this valve works over time using special heart ultrasound tests.
This study compares regular monitoring (“clinical surveillance”) versus replacing the aortic valve using a minimally invasive procedure called TAVR for people with moderate aortic stenosis. It aims to see which approach better reduces symptoms or heart damage over time.
Hear when a new Aortic Stenosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.